New York, New York, United States Arcus Ventures appeared to be the VC, which was created in 2007. The company was established in North America in United States. The main department of described VC is located in the New York.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical, Biotechnology. The fund has specific favorite in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Epic Sciences, Cleave Therapeutics, Exosome Diagnostics For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The important activity for fund was in 2011. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2015. The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. Comparing to the other companies, this Arcus Ventures performs on 4 percentage points less the average number of lead investments.
The fund was created by James B. Dougherty, Steven L. Soignet. Besides them, we counted 2 critical employees of this fund in our database.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Arcus Ventures, startups are often financed by Flybridge Capital Partners, Polaris Partners, NGN Capital. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, NGN Capital, Forbion Capital Partners. In the next rounds fund is usually obtained by Beringea, NGN Capital, Forbion Capital Partners.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Concord New Energy Group | - |
| Cystic Fibrosis Foundation | Bethesda, Maryland, United States |
| Entresmart | - |
| First Capital Partners | Nebraska, Omaha, United States |
| Hangzhou Chuangyu Touzi Zixun Co., Ltd. | China, Hangzhou, Zhejiang |
| Hankyu | Japan, Osaka, Osaka Prefecture |
| iNetworks 360 | China, Hong Kong, Hong Kong Island |
| New Jersey Devils | New Jersey, Newark, United States |
| Quero Education | Brazil, Pernambuco, Sao Paulo |
| Tellhow | China, Futian, Guangdong |
| W.R. Huff Asset Management Co. LLC. | Florida, Stuart, United States |
| Wutong Ideal Capital Management | Beijing, Beijing, China |
| Yelin Lapidot Investment House | Israel, Tel Aviv, Tel Aviv District |
| Yingchuang Touzi | China, Shanghai |
| Yixing Touzi | China, Shanghai |
| Yorkshire Bank | England, Leeds, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cleave Therapeutics | $12M | 06 Aug 2019 | San Francisco, California, United States | ||
Exosome Diagnostics | $30M | 24 Jul 2017 | New York, New York, United States | ||
Cleave Therapeutics | $37M | 17 Aug 2016 | San Francisco, California, United States | ||
Exosome Diagnostics | $16M | 07 Jan 2016 | New York, New York, United States | ||
Exosome Diagnostics | $17M | 02 Sep 2015 | New York, New York, United States | ||
XTuit Pharmaceuticals | $22M | 11 Jun 2015 | Cambridge, Massachusetts, United States | ||
TRACON Pharmaceuticals | $27M | 22 Sep 2014 | San Diego, California, United States | ||
Epic Sciences | $30M | 30 Jul 2014 | San Diego, California, United States | ||
Exosome Diagnostics | $27M | 11 Mar 2014 | New York, New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cleave Therapeutics | $12M | 06 Aug 2019 | San Francisco, California, United States | ||
Exosome Diagnostics | $30M | 24 Jul 2017 | New York, New York, United States | ||
Cleave Therapeutics | $37M | 17 Aug 2016 | San Francisco, California, United States | ||
Exosome Diagnostics | $16M | 07 Jan 2016 | New York, New York, United States | ||
Exosome Diagnostics | $17M | 02 Sep 2015 | New York, New York, United States | ||
XTuit Pharmaceuticals | $22M | 11 Jun 2015 | Cambridge, Massachusetts, United States | ||
TRACON Pharmaceuticals | $27M | 22 Sep 2014 | San Diego, California, United States | ||
Epic Sciences | $30M | 30 Jul 2014 | San Diego, California, United States | ||
Exosome Diagnostics | $27M | 11 Mar 2014 | New York, New York, United States |
